Sugi Predict

Sugi Predict / Compounds / SCHEMBL431636

SCHEMBL431636

SCHEMBL431636

COCCOc1cccc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LIPG Q9Y5X9 6/20 0.46
▸ LPL P06858 5/20 0.46
▸ MAPK1 P28482 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ DGAT1 O75907 1/20 0.36
▸ SYK P43405 1/20 0.36
▸ HIF1A Q16665 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclopentane SCHEMBL28665515 0.96 LPL (0.43) LIPGLPLMAPK1CYP1A2CYP2D6
SCHEMBL20745594 0.96 LPL (0.43) LIPGLPLMAPK1CYP1A2CYP2D6
SCHEMBL18124821 0.94 LIPG (0.50) LIPGLPLMAPK1CA1CA2
SCHEMBL1830523 0.93 LPL (0.48) LIPGLPLMAPK1CYP1A2CYP2D6
SCHEMBL31150275 0.93 LPL (0.48) LIPGLPLMAPK1CYP1A2CYP2D6
SCHEMBL4513327 0.90 LPL (0.47) LIPGLPLMAPK1CA1CA2
SCHEMBL2801619 0.88 LPL (0.51) LIPGLPLALDH1A1TSHR
SCHEMBL1829600 0.87 KDM4E (0.48) LIPGLPLMAPK1CYP1A2CYP2D6
SCHEMBL23732854 0.85 LIPG (0.46) LIPGLPLCA1CA2CA9
SCHEMBL4602862 0.85 LPL (0.49) LIPGLPLCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034127-A1 TREATMENT OF GVHD KADMON CORP LLC (FR) 2026-02-05 — — US disclosed
EP-4637754-A2 SELECTIVE BET INHIBITORS AND USES THEREOF Tay Therapeutics Limited (GB) 2025-10-29 — — EP disclosed
US-12246014-B2 Azetidine derivatives LIGAND UK DEVELOPMENT LIMITED (GB) 2025-03-11 — — US disclosed
US-20250074892-A1 CARBONYL BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-03-06 — — US disclosed
EP-4446319-A1 CARBONYL BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2024-10-16 — — EP disclosed
WO-2024138201-A2 SELECTIVE BET INHIBITORS AND USES THEREOF Tay Therapeutics Limited (GB) 2024-06-27 — — WO disclosed
EP-4116293-A2 RHO KINASE INHIBITORS Kadmon Corporation, LLC (US) 2023-01-11 — — EP disclosed
US-20220395501-A1 TREATMENT OF GVHD KADMON CORP LLC (US) 2022-12-15 — — US disclosed
US-20220395501-A1 TREATMENT OF GVHD KADMON CORP LLC (US) 2022-12-15 — — US disclosed
US-11453675-B2 Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders Bial—R&D Investments, S.A. (PT) 2022-09-27 — — US disclosed
WO-2009109743-A1 AZETIDINE DERIVATIVES VERNALIS (R&D) LTD. (GB) 2009-09-11 — — WO disclosed
WO-2009109743-A1 AZETIDINE DERIVATIVES VERNALIS (R&D) LTD. (GB) 2009-09-11 — — WO disclosed
US-20090098218-A1 Tetracyclic Lactame Derivatives NOVARTIS AG 2009-04-16 — — US disclosed
US-20090098218-A1 Tetracyclic Lactame Derivatives NOVARTIS AG 2009-04-16 — — US disclosed
US-20090098218-A1 Tetracyclic Lactame Derivatives NOVARTIS AG 2009-04-16 — — US disclosed
EP-2029543-A2 SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS Wyeth (US) 2009-03-04 — — EP disclosed
WO-2009010488-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS NOVARTIS AG (CH) 2009-01-22 — — WO disclosed
WO-2009010488-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS NOVARTIS AG (CH) 2009-01-22 — — WO disclosed
WO-2007146376-A2 SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS WYETH (US) 2007-12-21 — — WO disclosed
US-20070287708-A1 Substituted 3-cyanopyridines as protein kinase inhibitors WYETH LLC 2007-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034127-A1 TREATMENT OF GVHD ROCK2, RHOA, MYH2 LIPG 2667/4885LPL 4037/4885MAPK1 1218/4885
US-12246014-B2 Azetidine derivatives FAAH2, FAAH, APEH LIPG 1682/4885LPL 355/4885MAPK1 2638/4885
US-11453675-B2 Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders GBA1, GAA, GBA2 LIPG 2847/4885LPL 1471/4885MAPK1 4176/4885
US-20070287708-A1 Substituted 3-cyanopyridines as protein kinase inhibitors CNKSR1, MAP3K1, MAP3K7 LIPG 3369/4885LPL 4289/4885MAPK1 28/4885
US-20250074892-A1 CARBONYL BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF RIPK1, RIPK3, RIPK4 LIPG 4101/4885LPL 4774/4885MAPK1 83/4885
US-20220395501-A1 TREATMENT OF GVHD ROCK2, ROCK1, RHOXF2 LIPG 2426/4885LPL 4348/4885MAPK1 2330/4885
US-20090098218-A1 Tetracyclic Lactame Derivatives TNF, RPS6KB2, RPS6KA2 LIPG 3164/4885LPL 3069/4885MAPK1 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.